Factor Therapeutics Limited (ASX:FTT) entered into a term sheet agreement to acquire PowerLime, Inc. on April 20, 2021. On July 26, 2021, Factor Therapeutics Limited entered into a conditional share purchase agreement to acquire PowerLime, Inc. PowerLime holds an option under an Option Agreement to acquire a land parcel located in Early County, south Georgia, USA. Under the PowerLime Option Agreement, a second option payment is payable by on or before July 31, 2021 in order to purchase the real property located in south Georgia, USA. In accordance with the share purchase agreement, Factor will advance $150,000 (AUD 0.19 million) for second option payment. Post acquisition, Power Line Services, Inc. will become wholly owned subsidiary of Factor Therapeutics Limited. Factor proposes to issue 187.5 million shares to PowerLime’s shareholders at AUD 0.004 per share representing an acquisition value of AUD 0.75 million. In addition Factor will issue 62.5 million options to PowerLime shareholders and 46.9 million options to the management team. The options will be exercisable at AUD 0.012 per option and have a four year term. Securities issued as consideration for the transaction will be subject to a mandatory restriction period of 24 months. Dominic Allen will be appointed as an Executive Director, and Anastasios Arima as a Non-Executive Director. John Michailidis and Melanie Farris will retire from the Board upon the Factor Therapeutics’s readmission to ASX. As a result of the Transaction, Factor Therapeutics proposes to change its name to ‘Dominion Minerals Limited’ and its ASX code to ‘DML’. Closing of the Transaction is conditional upon various conditions precedent being satisfied or waived, including but not limited to: PowerLime paying the second option payment under the Option Agreement to the current landholder, and negotiating the terms of purchase for the land; Factor having obtained all required Shareholder approvals to the Transaction; Factor and PowerLIme completing satisfactory due diligence investigations; and Factor granting the PowerLime Shareholders the right to nominate two representative directors to Factor, upon Official Quotation. As of July 20, 2021, Factor Therapeutics received in-principle advice from ASX. Factor Therapeutics Limited (ASX : FTT) completed the acquisition of PowerLime, Inc on September 27, 2021.